Johnson & Johnson (JNJ) News
NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD
261.44+4.96 (+1.93%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
JNJ news summary
We found 50 recent headlines mentioning Johnson & Johnson (JNJ): 27 in the past week and 44 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. For price context, JNJ is up 1.93% at $261.44. The most recent story, "2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)", was published by Nasdaq on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Johnson & Johnson headlines
- 2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)Key PointsJohnson & Johnson's 64 consecutive years of dividend increases make it a true Dividend King anchored by a growing healthcare pipeline.NasdaqJNJ, O, APO, KVUE
- Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasisSeeking Alpha
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.NasdaqJNJ, AMGN, TEVA
- Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis(RTTNews) - Johnson & Johnson (JNJ), a healthcare company focused on innovative medicines and medical technologies, reported two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE…NasdaqJNJ, ET
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasisPhase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a…PR Newswire
- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeHalozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.NasdaqHALO, JNJ, MRK, ARGX
- Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKDBAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.NasdaqREGN, JNJ
- Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Nasdaq
- Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsPFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.NasdaqPFE, AZN, JNJ, MRK
- Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors ExpectKey PointsJohnson & Johnson’s decision to separate from its consumer health segment could help raise top-line growth over the medium term.NasdaqJNJ, ISRG
- Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesBesides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared…Nasdaq
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.NasdaqPFE, JNJ
- Pharma lobby group sues Trump administration over MFN pricingSeeking Alpha
- Notable ETF Inflow Detected - VT, JNJ, V, MALooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an…NasdaqVT, JNJ, V, MA
- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.NasdaqHALO, JNJ, ARGX, HOWL
- PFE vs. JNJ: Which Stock Is the Better Value Option?PFE vs. JNJ: Which Stock Is the Better Value Option?NasdaqPFE, JNJ
- Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could drive a stronger second half.NasdaqJNJ, BSX, MDT, SYK
- Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Nasdaq
- Johnson & Johnson: The Next Patent Cliff Will Test A Replacement Engine That It Is Already Working OnSeeking Alpha
- Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to NoteJohnson & Johnson (JNJ) closed at $252.83 in the latest trading session, marking a -1.25% move from the prior day.Nasdaq
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationJ&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.NasdaqJNJ, PFE, NVO, LLY
- 2 Beaten-Down Stocks Worth Buying and Holding for the Next DecadeKey PointsNetflix's large ecosystem offers attractive monetization opportunities if it can boost engagement.NasdaqISRG, NFLX, JNJ, MDT
- Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.Key PointsHealthcare stocks are a great place to find recession-resistant dividend stocks, including Dividend King Johnson & Johnson.Nasdaq
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingLLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.NasdaqLLY, AZN, JNJ, ABBV
- Is Buying Nike Stock Now a Brilliant Move or a Disaster Waiting to Happen? Here's the Answer and What to Do Next.Key PointsNike beat on earnings per share but fell short of revenue expectations in its 2027 first-quarter earnings report.NasdaqNKE, JNJ, SIRI
- Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.Key PointsEli Lilly is seeing huge demand for its GLP-1 weight-loss drugs and using the cash influx to diversify.NasdaqJNJ, LLY, MDT
- The Stock Market Just Flashed a Warning Signal Seen Only Twice in 155 Years. Here Are 3 Stocks That Can Weather What History Says Comes Next.Key PointsThe S&P 500 Shiller CAPE ratio has historically been a good predictor of steep market sell-offs.NasdaqJNJ, PG, EPD
- 3 of the Best ETFs to Buy and Hold if a Recession Is ComingKey PointsVHT is a diversified play on the non-cyclical healthcare sector.NasdaqMRK, MSFT, GOOGL, AAPL
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic…NasdaqABBV, AZN, CBLL, CDXS
- J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to WatchJNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.NasdaqJNJ, AZN, AMGN, ABBV
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueTepid market response or not, Jabil’s (NYSE: JBL) recent double-beat earnings report was a buy signal, reinforcing the thesis that has driven shares thus far and strengthening the forward…NasdaqJBL, AAPL, CSCO, JNJ
- History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.Key PointsJohnson & Johnson has significantly outperformed Medtronic over the past decade.NasdaqJNJ, MDT
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.NasdaqABBV, JNJ, MRK, LLY
- Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.Key PointsTwenty-four of 32 analysts covering Intuitive Surgical rate the stock as a "buy" or "strong buy."NasdaqISRG, JNJ, SYK, MDT
- If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's ThisKey PointsA bull market is a great time to own stocks, as many may soar and will increase the value of your portfolio.NasdaqCOST, AAPL, JNJ, MU
- 3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record HighKey PointsJohnson & Johnson has a deep and diversified pharmaceutical portfolio.NasdaqJNJ, ISRG
- Johnson & Johnson: Strong Catalysts, But I'm Staying At HoldSeeking Alpha
- Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?Key PointsIntuitive Surgical's stock has declined sharply this year due to several factors.NasdaqISRG, JNJ, MDT, SPGI
- 2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVieSeeking AlphaJNJ, ABBV
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.NasdaqJNJ, LLY, GILD, PTGX
- Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking AlphaJNJ, DB
- Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaJNJ, MS
- These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy.Key PointsTo brace against market pullbacks, add some defensive stocks or funds to your mix.NasdaqVHT, VZ, WMT, MRK
- Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than HalfSeeking Alpha
- Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Monday announced the appointment of Chris Benecchi as Chief Operating Officer (COO).NasdaqIVA, JNJ, TAK
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.Key PointsJ&J's portfolio primarily includes small biotech and medtech companies.NasdaqPTGX, JNJ, LAB, XNCR
- Top Analyst Reports for JPMorgan, Johnson & Johnson & MastercardJPMorgan, Johnson & Johnson and Mastercard headline today's research, with growth drivers and key risks shaping each stock's outlook.NasdaqJPM, GD, ACN, MA
- Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales PushSeeking Alpha